ID   RCC BA85#21
AC   CVCL_T986
SY   RCC85#21; RCC BA85#21 (ELTHEM); BA85-RCC; Elthem
DR   ECACC; 13051601
DR   Wikidata; Q54949443
RX   Patent=US8128923;
RX   PubMed=27278998;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 04006.
CC   Doubling time: 72 hours (PubMed=27278998).
CC   Microsatellite instability: Stable (MSS) (PubMed=27278998).
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): ECACC
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 10,12
ST   D5S818: 12
ST   D7S820: 10
ST   TH01: 6,8
ST   TPOX: 8,10
ST   vWA: 14,18
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 29-06-23; Version: 12
//
RX   Patent=US8128923;
RA   Ranieri E., Battaglia M., Wolfgang H., Gesualdo L.;
RT   "Renal carcinoma cell line and uses thereof.";
RL   Patent number US8128923, 06-Mar-2012.
//
RX   PubMed=27278998; DOI=10.3892/ijo.2016.3544;
RA   Prattichizzo C., Gigante M., Pontrelli P., Stella A., Rocchetti M.T.,
RA   Gigante M., Maiorano E., Herr W., Battaglia M., Gesualdo L.,
RA   Ranieri E.;
RT   "Establishment and characterization of a highly immunogenic human
RT   renal carcinoma cell line.";
RL   Int. J. Oncol. 49:457-470(2016).
//